Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Fortress Biotech Presents Positive Data from the Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia
Fortress Biotech Presents Positive Data from the Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia
Fortress Biotech Presents Positive Data from the Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia
Submitted by
admin
on May 18, 2016 - 11:18am
Source:
Yahoo
News Tags:
Fortress Biotech
clinical trials
CNDO-109
acute myeloid leukemia
Headline:
Fortress Biotech Presents Positive Data from the Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia
Do Not Allow Advertisers to Use My Personal information
